POTASSIUM CHLORIDE IN SODIUM CHLORIDE INJECTION USP SOLUTION

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Koupit nyní

Aktivní složka:

SODIUM CHLORIDE; POTASSIUM CHLORIDE

Dostupné s:

BAXTER CORPORATION

ATC kód:

B05BB01

INN (Mezinárodní Name):

ELECTROLYTES

Dávkování:

450MG; 150MG

Léková forma:

SOLUTION

Složení:

SODIUM CHLORIDE 450MG; POTASSIUM CHLORIDE 150MG

Podání:

INTRAVENOUS

Jednotky v balení:

1000ML

Druh předpisu:

Ethical

Terapeutické oblasti:

REPLACEMENT PREPARATIONS

Přehled produktů:

Active ingredient group (AIG) number: 0213340004; AHFS:

Stav Autorizace:

MARKETED

Datum autorizace:

2008-03-31

Charakteristika produktu

                                Potassium Chloride in 0.45% Sodium Chloride Injection, USP Prescribing
Information
_ _
_Page 1 of 14_
PRESCRIBING INFORMATION
POTASSIUM CHLORIDE IN 0.45% SODIUM CHLORIDE INJECTION, USP
IN PLASTIC CONTAINER
VIAFLEX
Container
20 mmol/L Potassium Chloride in 0.45% Sodium Chloride Injection
SOLUTION FOR INFUSION
Solutions Affecting the Electrolyte Balance
BAXTER CORPORATION
Mississauga, ON L5N 0C2
Date of Revision:
December 10, 2018
Control No. 221539
Potassium Chloride in 0.45% Sodium Chloride Injection, USP Prescribing
Information
_ _
_Page 2 of 14_
TABLE OF CONTENTS
SUMMARY PRODUCT INFORMATION
....................................................................................3
INDICATIONS AND CLINICAL USE
..........................................................................................3
CONTRAINDICATIONS
...............................................................................................................3
WARNINGS AND PRECAUTIONS
..............................................................................................3
SPECIAL POPULATIONS
.............................................................................................................7
ADVERSE REACTIONS
................................................................................................................8
DRUG INTERACTIONS
................................................................................................................8
DOSAGE AND ADMINISTRATION
............................................................................................9
INSTRUCTIONS FOR USE AND HANDLING AND DISPOSAL
............................................10
DIRECTIONS FOR USE OF VIAFLEX PLUS PLASTIC CONTAINER
..................................11
OVERDOSE
..................................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
........................................................................13
STORAGE AND STABILITY
..................
                                
                                Přečtěte si celý dokument
                                
                            

Dokumenty v jiných jazycích

Charakteristika produktu Charakteristika produktu francouzština 10-12-2018

Vyhledávejte upozornění související s tímto produktem